MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Exact Sciences Corporation Operating Income 2011-2025 | EXAS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Exact Sciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -876 M | -67.8 M | -594 M | -856 M | -768 M | -234 M | -159 M | -118 M | -169 M | -159 M | -101 M | -46.8 M | -52.6 M | -28.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -28.8 M | -876 M | -302 M |
Quarterly Operating Income Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.5 M | -2.15 M | -96 M | - | -39.4 M | -26.3 M | -107 M | - | 6.85 M | -76.9 M | -77.1 M | - | -138 M | -160 M | -177 M | - | -162 M | -172 M | -301 M | - | -203 M | -67 M | -82.4 M | -96.1 M | -35.7 M | -33.9 M | -68.1 M | -49.3 M | -40.9 M | -32.7 M | -36.5 M | -23 M | -28.4 M | -31.4 M | -35.5 M | -37.7 M | -38.3 M | -45.1 M | -47.9 M | -40.4 M | -43.3 M | -39.4 M | -36 M | -32.6 M | -32.2 M | -19.6 M | -16.2 M | -12.3 M | -11.2 M | -12.4 M | -10.9 M | -14 M | -13 M | -14.9 M | -10.7 M | -9.94 M | -7.84 M | -6.64 M | -4.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.85 M | -301 M | -55.1 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 17.13 | 1.66 % | $ 99.4 M |  Israel |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 12.15 | 2.14 % | $ 345 M | Israel |
 |
DexCom
DXCM
|
598 M | $ 66.06 | -1.34 % | $ 25.5 B |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.0 | 1.59 % | $ 172 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.56 | -3.7 % | $ 1.98 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.95 | 0.82 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 227.29 | 0.42 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.94 | -0.74 % | $ 815 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
NeoGenomics
NEO
|
-92.1 M | $ 12.15 | 2.53 % | $ 1.54 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 6.84 | -0.36 % | $ 1.48 B | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.9 | -3.21 % | $ 1.07 B | USA |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 2.12 | - | $ 538 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 101.74 | -3.33 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.35 | -6.42 % | $ 107 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.46 | -0.62 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.3 | -13.39 % | $ 8.8 M | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 24.67 | -1.2 % | $ 32 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 224.13 | 0.84 % | $ 40.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | $ 45.14 | -0.21 % | $ 10 B | Niderland |
 |
Guardant Health
GH
|
-444 M | $ 103.55 | 1.45 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Sotera Health Company
SHC
|
298 M | $ 16.76 | -0.42 % | $ 4.74 B | USA |
 |
Soleno Therapeutics
SLNO
|
-188 M | $ 49.79 | -4.25 % | $ 2 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Thermo Fisher Scientific
TMO
|
7.34 B | $ 574.27 | 0.46 % | $ 219 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 134.66 | -0.16 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 197.59 | 2.36 % | $ 10.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.96 | -10.6 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 31.39 | 1.47 % | $ 1.88 B | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 184.04 | 0.81 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 7.07 | -2.01 % | $ 641 M | USA |